Cost-effectiveness of rotavirus vaccination in the Netherlands; The results of a consensus model

BMC Public Health

Volumn 11, Issue , 2011, Pages

  Rozenbaum, Mark H ^a   Mangen, Marie Josee J ^b   Giaquinto, Carlo ^c   Wilschut, Jan C ^d   Hak, Eelko ^a   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; CONSENSUS; COST BENEFIT ANALYSIS; ECONOMICS; GASTROENTERITIS; HUMAN; IMMUNOLOGY; NETHERLANDS; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; ROTAVIRUS; ROTAVIRUS INFECTION; VIROLOGY;

CHILD, PRESCHOOL; CONSENSUS; COST-BENEFIT ANALYSIS; GASTROENTERITIS; HUMANS; IMMUNIZATION PROGRAMS; NETHERLANDS; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 79960065102     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-11-462     Document Type: Article

References (44)

1. Global, regional, and national causes of child mortality in 2008: a systematic analysis. RE Black S Cousens HL Johnson JE Lawn I Rudan DG Bassani P Jha H Campbell CF Walker R Cibulskis T Eisele L Liu C Mathers, Lancet 2010
2. Global illness and deaths caused by rotavirus disease in children. UD Parashar EG Hummelman JS Bresee MA Miller RI Glass, Emerg Infect Dis 2003 9 565 572 12737740 (Pubitemid 36529515)
3. Rotavirus vaccines. World Health Organization, Weekly Epidemiological Record 2007 32 285 296 2009
4. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe: executive summary. T Vesikari DP Van C Giaquinto J Gray J Mrukowicz R Dagan A Guarino H Szajewska V Usonis, J Pediatr Gastroenterol Nutr 2008 46 615 618 10.1097/MPG. 0b013e31816e213a 18493224
5. Rotavirus overview. DI Bernstein, Pediatr Infect Dis J 2009 28 50 S53 10.1097/INF.0b013e3181967bee 19252423
6. Public health economics of vaccines in the Netherlands: methodological issues and application. MJ Postma, Journal of Public Health 2008 16 267 10.1007/s10389-008-0200-2
7. The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. LM Goossens B Standaert N Hartwig AM Hovels MJ Al, Vaccine 2008 26 1118 1127 10.1016/j.vaccine.2007.11.070 18215445
8. The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe. M Jit J Bilcke MJ Mangen H Salo H Melliez WJ Edmunds Y Yazdan P Beutels, Vaccine 2009 27 6121 6128 10.1016/j.vaccine.2009.08.030 19715781
9. Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program? MJ Mangen YT van Duynhoven H Vennema PW van AH Havelaar HE de Melker, Vaccine 2010 28 2624 2635 10.1016/j.vaccine.2010.01.014 20109593
10. Assessing the introduction of universal rotavirus vaccination in the Netherlands. TP Zomer YT van Duynhoven MJ Mangen NA van der Maas H Vennema H Boot HE de Melker, Vaccine 2008 26 3757 3764 10.1016/j.vaccine.2008.04.039 18514975
11. Efficacy of rotateq, the pentavalent rotavirus vaccine, between doses: potential benefits of early protection. T Vesikari P Dennehy D Matson R Itzler M Dallas M Goveia M DiNubile P Heaton J Lawrence M Cairlet, 2nd congress of the European Academy of Paediatrics. Nice, France 2010 24-28 October, 2008 (Abstract)
12. A comparison of gastroenteritis in a general practice-based study and a community-based study. MA de Wit LM Kortbeek MP Koopmans CJ de Jager WJ Wannet AI Bartelds YT van Duynhoven, Epidemiol Infect 2001 127 389 397 11811870 (Pubitemid 34092784)
13. Gastroenteritis in sentinel general practices, The Netherlands. MA de Wit MP Koopmans LM Kortbeek NJ van Leeuwen AI Bartelds YT van Duynhoven, Emerg Infect Dis 2001 7 82 91 10.3201/eid0701.010113 11266298 (Pubitemid 32173337)
14. Sensor, a population-based cohort study on gastroenteritis in the Netherlands: incidence and etiology. MA de Wit MP Koopmans LM Kortbeek WJ Wannet J Vinje LF van AI Bartelds YT van Duynhoven, Am J Epidemiol 2001 154 666 674 10.1093/aje/154.7.666 11581101 (Pubitemid 32888785)
15. Etiology of gastroenteritis in sentinel general practices in the netherlands. MA de Wit MP Koopmans LM Kortbeek NJ van Leeuwen J Vinje YT van Duynhoven, Clin Infect Dis 2001 33 280 288 10.1086/321875 11438890 (Pubitemid 32664828)
16. Hospital admissions for rotavirus infection in the Netherlands. MA de Wit MP Koopmans JF van der Blij YT van Duynhoven, Clin Infect Dis 2000 31 698 704 10.1086/314025 11017818 (Pubitemid 32295489)
17. Nosocomial rotavirus infection in European countries: a review of the epidemiology, severity and economic burden of hospital-acquired rotavirus disease. O Gleizes U Desselberger V Tatochenko C Rodrigo N Salman Z Mezner C Giaquinto E Grimprel, Pediatr Infect Dis J 2006 25 12 S21 10.1097/01.inf. 0000197563.03895.91 16397425
18. Estimating the number of deaths with rotavirus as a cause in England and wales. M Jit R Pebody M Chen N Andrews WJ Edmunds, Hum Vaccin 2007 3 23 26 10.4161/hv.3.1.3748 17264682
19. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care'' disease impact in Belgium. J Bilcke DP Van P Beutels, Med Decis Making 2009 29 33 50 10.1177/0272989X08324955 18948433
20. Hospitalizations associated with rotavirus gastroenteritis in Spain, 2001-2005. A Lopez-de-Andres R Jimenez-Garcia P Carrasco-Garrido A Alvaro-Meca PG Galarza AG de Miguel, BMC Public Health 2008 8 109 10.1186/1471-2458-8-109 18397512
21. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. T Vesikari R Itzler A Karvonen T Korhonen DP Van U Behre G Bona L Gothefors PM Heaton M Dallas MG Goveia, Vaccine 2009 28 345 351 10.1016/j.vaccine.2009.10.041 19879226
22. Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. T Vesikari A Karvonen SA Ferrante M Ciarlet, Eur J Pediatr 2010 169 1379 1386 10.1007/s00431-010- 1242-3 20559656
23. Sustained Efficacy of the Pentavalent Rotavirus Vaccine, RV5, up to 3.1 Years Following the Last Dose of Vaccine. T Vesikari A Karvonen SA Ferrante BJ Kuter M Ciarlet, Pediatr Infect Dis J 2010
24. Rotateq - high and sustained efficacy against any rotavirus serotype to reduce rotavirus disease in Europe. T Vesikari P van Damme L Gothefors M Goveia, 2nd Congress of the European Academy of Paediatrics, Nice, France 2008
25. Health-related quality of life lost to rotavirus-associated gastroenteritis in children and their parents: a Canadian prospective study. M Brisson M Senecal M Drolet JA Mansi, Pediatr Infect Dis J 2010 29 73 75 10.1097/INF.0b013e3181b41506 19907361
26. Estimating utility scores in young children with acute rotavirus gastroenteritis in the UK. A Martin S Cottrell B Standaert, J Med Econ 2008 11 471 484 10.3111/13696990802321047 19450099
27. Priorization of foodborne pathogens. JM Kemmeren MJJ Mangen YTHP van Duynhoven AH Havelaar, Bilthoven: National Institute for Public Health and the Environment 2006 Report No.: 330080001, 2006
28. Rotavirus, in priority setting of foodborne pathogens. Disease burden and costs of selected enteric pathogens. J Kemmeren MJJ Mangen YTHP van Duynhoven AH Havelaar, Bilthoven 2006 http://www.rivm.nl/bibliotheek/rapporten/330080001. pdf RIVM report330080001/2006
29. Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar). MH Rozenbaum AJ Hoek E Hak MJ Postma, Vaccine 2010 28 2367 2369 10.1016/j.vaccine.2010.01.005 20085833
30. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. MH Rozenbaum EA Sanders AJ van Hoek AG Jansen A van der Ende G van den Dobbelsteen GD Rodenburg E Hak MJ Postma, BMJ 2010 340 2509 10.1136/bmj.c2509 20519267
31. Need for differential discounting of costs and health effects in cost effectiveness analyses. WB Brouwer LW Niessen MJ Postma FF Rutten, BMJ 2005 331 446 448 10.1136/bmj.331.7514.446 16110075 (Pubitemid 41176388)
32. Delayed onset and diminished magnitude of rotavirus activity - United States, November 2007-May 2008. MMWR Morb Mortal Wkly Rep 2008 57 697 700 18583958
33. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. FT Wang TC Mast RJ Glass J Loughlin JD Seeger, Pediatrics 2010 125 208 e213 10.1542/peds.2009-1246 20100757
34. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. JE Tate CA Panozzo DC Payne MM Patel MM Cortese AL Fowlkes UD Parashar, Pediatrics 2009 124 465 471 10.1542/peds.2008- 3528 19581260
35. Reduction in hospitalizations for diarrhea and rotavirus infections in New York state following introduction of rotavirus vaccine. HG Chang PF Smith B Tserenpuntsag K Markey U Parashar DL Morse, Vaccine 2010 28 754 758 10.1016/j.vaccine.2009.10.075 19896451
36. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. AT Curns CA Steiner M Barrett K Hunter E Wilson UD Parashar, J Infect Dis 2010 201 1617 1624 10.1086/652403 20402596
37. Early evidence for direct and indirect effects of the infant rotavirus vaccine program in Queensland. SB Lambert CE Faux L Hall FA Birrell KV Peterson CE Selvey TP Sloots MD Nissen K Grimwood, Med J Aust 2009 191 157 160 19645646
38. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. EJ Field H Vally K Grimwood SB Lambert, Pediatrics 2010 126 506 e512 10.1542/peds.2010-0443 20732946
39. A mathematical model of the indirect effects of rotavirus vaccination. T Van Effelterre M Soriano-Gabarro S Debrus NE Claire J Gray, Epidemiol Infect 2010 138 884 897 10.1017/S0950268809991245 20028612
40. Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination. E Shim AP Galvani, Vaccine 2009 27 4025 4030 10.1016/j.vaccine. 2009.04.030 19389452
41. Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes. KH Jacob-Tacken MA Koopmanschap WJ Meerding JL Severens, Health Econ 2005 14 435 443 10.1002/hec.948 15497201 (Pubitemid 40723852)
42. Guidelines for costing research, methods and standardized prices for economic evaluations in health care. JB Oostenbrink CAM Bouwmans MA Koopmanschap FHH Rutten, Health Care Insurance Board Diemen, The Netherlands 2004
43. Possible Role of Cost-Effectiveness of HPV Vaccination within the Decision Context on Inclusion of HPV in the Country-Specific National Immunization Programs. MH Rozenbaum C Grahlmann MJ Postma, The Open Pharmacoeconomics & Health Economics Journal 2010 2 1 10 21561394
44. Cost-effectiveness of varicella vaccination programs: an update of the literature. MH Rozenbaum AJ van Hoek S Vegter MJ Postma, Expert Rev Vaccines 2008 7 753 782 10.1586/14760584.7.6.753 18665775